0000880771-15-000040.txt : 20150318 0000880771-15-000040.hdr.sgml : 20150318 20150318170837 ACCESSION NUMBER: 0000880771-15-000040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150316 FILED AS OF DATE: 20150318 DATE AS OF CHANGE: 20150318 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun CENTRAL INDEX KEY: 0001291656 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 15710770 MAIL ADDRESS: STREET 1: SCICLONE PHARMACEUTICALS, INC. STREET 2: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 rivet-form4.xml PRIMARY DOCUMENT X0306 4 2015-03-16 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001291656 Cheung Wilson Wai-Shun 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 0 1 0 0 CFO & Senior VP, Finance Stock Option (right to buy) 8.83 2015-03-16 4 A 0 84000 0 A 2025-03-16 Common Stock 84000 84000 D Restricted Stock Unit 2015-03-16 4 A 0 12000 0 A Common Stock 12000 49500 D Granted under the Issuer's 2005 Equity Incentive Plan. 25% of such shares vest from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment. /s/Friedhelm Blobel, Attorney-in-Fact for: Wilson W. Cheung 2015-03-18